Home
Login Register
CFM    Last:0.051   -

MEDICAL CLEANTECH PPLE GLOVE ALL THEY GOT

 Post Reply 1961-1980 of 2466
 
blissbao     07-Jun-2021 10:42  
Contact    Quote!
Look at Medtech intl .   Was also .20 cts when Philips put it on the restricted buy list .   Still zoom passed the $1.00 mark .   This new development still has more room if the BB keep loading . 

PQTPQK      ( Date: 07-Jun-2021 10:16) Posted:

up alot already ...

TokKong71      ( Date: 07-Jun-2021 10:14) Posted:

So today will surpass 0.2c?


 
 
PQTPQK     07-Jun-2021 10:16  
Contact    Quote!
up alot already ...

TokKong71      ( Date: 07-Jun-2021 10:14) Posted:

So today will surpass 0.2c?

 
 
TokKong71     07-Jun-2021 10:14  
Contact    Quote!
So today will surpass 0.2c?
 

 
Observers     07-Jun-2021 10:08  
Contact    Quote!
Diamond Hands! dont know why people bother to read annual reports.
 
 
papayaface     07-Jun-2021 09:51  
Contact    Quote!
SGX & broking houses cant do anything against the BBs. Lets hope for 20 cts before lunch. Good luck   

easywin      ( Date: 07-Jun-2021 09:46) Posted:

Repeat as last time Blumont?

 
 
tanstg     07-Jun-2021 09:49  
Contact    Quote!
Just be careful at this stage. it may U-turn at any time - no one knows what has cook this counter up. The deal has yet to confirm as mentioned in the announcement with SGX.
 

 
tankoksee     07-Jun-2021 09:49  
Contact    Quote!
after 20 cts > 50 cts long term target ..ototsmiley
 
 
Blowyouoff     07-Jun-2021 09:49  
Contact    Quote!
You flip flop

your creditabiltiy has lost since Medtec thread 

gregtan123      ( Date: 07-Jun-2021 09:16) Posted:

Relax bro, I play reverse psychology, I sold 0.178 haha but sian now 0.187 HAHA. made some kopi lui $$$. forum must play risk psychology.

Blowyouoff      ( Date: 06-Jun-2021 23:50) Posted:

Sing-swe owned by few china man

cansino is Chinese owned 

sing-swe doesn' t have to be manufacturer, being a licensed distributor may be good enough 

You try shorting in the morning and see how bad is the burnt.


 
 
easywin     07-Jun-2021 09:46  
Contact    Quote!
Repeat as last time Blumont?
 
 
Sgvale     07-Jun-2021 09:43  
Contact    Quote!
Wow. Sold last Fri. Don't dare chase. But buying momentum continue well pushing higher & higher
 

 
easywin     07-Jun-2021 09:42  
Contact    Quote!
Many retaillers missed the opporunity 20 cts very near
 
 
gregtan123     07-Jun-2021 09:16  
Contact    Quote!
Relax bro, I play reverse psychology, I sold 0.178 haha but sian now 0.187 HAHA. made some kopi lui $$$. forum must play risk psychology.

Blowyouoff      ( Date: 06-Jun-2021 23:50) Posted:

Sing-swe owned by few china man

cansino is Chinese owned 

sing-swe doesn' t have to be manufacturer, being a licensed distributor may be good enough 

You try shorting in the morning and see how bad is the burnt..

gregtan123      ( Date: 05-Jun-2021 17:38) Posted:

$CFM(5EB.SI) Given the recent share price spike from 3 cents to 16.3 cents, I went to poke around. This Company for Real Not? They List this CanSino Biologics Vaccine as their Product lei. Note CanSino is one of the ONE shot Gamechanger Vaccine and got EU European Union Approval. Can INS guru fact check? Nowadays SGX let these people do what they want?
 
They also got a lot of Test Kits.
 
Are they for real?
 
AD5-nCOV, a single-dose viral vector vaccine for COVID-19 developed by CanSino Biologics.
 
  • 65.7% efficacy in preventing moderate symptoms
  • 91% efficacy in preventing severe disease
  • EU GMP Certificate
  • Single-Dose COVID-19 Vaccine approval from NMPA
 
https://www.singswe.com/products/vaccine/


 
 
tankoksee     07-Jun-2021 09:14  
Contact    Quote!
yes

tankoksee      ( Date: 04-Jun-2021 16:10) Posted:

20 cts otot argggggggg

 
 
papayaface     07-Jun-2021 09:07  
Contact    Quote!
Huat ah. Up 3 fold already. Next station is 20.  Good luck

easywin      ( Date: 07-Jun-2021 09:05) Posted:

Wow , BBs very fear non stop buying.

 
 
tofudidi     07-Jun-2021 09:06  
Contact    Quote!
such a strong uptrend.. we clearly doubted bb
 

 
easywin     07-Jun-2021 09:05  
Contact    Quote!
Wow , BBs very fear non stop buying.
 
 
shk363     07-Jun-2021 09:04  
Contact    Quote!
this can be the gamestop of sgx... hold o to $1
 
 
Blowyouoff     06-Jun-2021 23:50  
Contact    Quote!
Sing-swe owned by few china man

cansino is Chinese owned 

sing-swe doesn' t have to be manufacturer, being a licensed distributor may be good enough 

You try shorting in the morning and see how bad is the burnt..

gregtan123      ( Date: 05-Jun-2021 17:38) Posted:

$CFM(5EB.SI) Given the recent share price spike from 3 cents to 16.3 cents, I went to poke around. This Company for Real Not? They List this CanSino Biologics Vaccine as their Product lei. Note CanSino is one of the ONE shot Gamechanger Vaccine and got EU European Union Approval. Can INS guru fact check? Nowadays SGX let these people do what they want?
 
They also got a lot of Test Kits.
 
Are they for real?
 
AD5-nCOV, a single-dose viral vector vaccine for COVID-19 developed by CanSino Biologics.
 
  • 65.7% efficacy in preventing moderate symptoms
  • 91% efficacy in preventing severe disease
  • EU GMP Certificate
  • Single-Dose COVID-19 Vaccine approval from NMPA
 
https://www.singswe.com/products/vaccine/


Joelton      ( Date: 05-Jun-2021 12:54) Posted:

CFM Holdings fields slew of SGXRegCo queries over its acquisition of pharma startup
 
SHARES of $ CFM: 5EB +32.77% have soared over the past two days, following its announcement on Thursday that it would acquire a 51 per cent stake in SING-SWE MM Biotechnology, which distributes and sells pharmaceutical products, for up to S$6.1 million.
 
When asked by the Singapore Exchange Regulation (SGX RegCo) who introduced this deal, CFM said a mutual business associate had introduced Fang Huasheng and Gao Hong to its chief executive officer, Janet Lim, for the purposes of distribution and sale of viral test kits in Singapore.
 
CFM had further commenced discussions and negotiations with the vendors for a potential collaboration, which led to the agreement of a proposed acquisition of SING-SWE MM Biotechnology, said the group in a bourse filing on Friday.
 
Mr Fang is an 83 per cent shareholder of New Energy Industry Sweden (NEIS), a firm originally appointed as the exclusive international distributor for the test kits. He is also a director of SING-SWE MM Biotechnology. Mr Gao is a vendor and director of SING-SWE MM Biotechnology.
 
CFM said no introducer or finders fees will be paid by the company for the proposed acquisition.
 
When asked whether an independent valuation had been done before the proposed acquisition, the group told SGX RegCo that SING-SWE MM Biotechnology had commenced business only recently it was " more of a startup" although it is operating in an industry that is currently well-established.
 
The proposed acquisition was therefore structured to be on an earn-out basis in order to reduce the risk to CFM and its shareholders, said the group.
 
No formal due diligence has been conducted on SING-SWE MM Biotechnology. That said, CFM noted that it had started reviewing preliminary information, including information related to the test kits and the distribution arrangements in place searches on shareholding and company information have also been conducted on SING-SWE MM Biotechnology and NEIS.
 
However, CFM stressed that such review is at a preliminary stage and formal due diligence is uncomplete.
 
Following the deal announcement on Thursday, CFM shares jumped 80.3 per cent to end at 11.9 Singapore cents amid heavy trading, up from when it last traded on May 28. Some growth momentum carried into Friday, with the counter closing up 32.8 per cent to 15.8 cents.
 
CFM had proposed to acquire 51 ordinary shares from vendors Mr Gao, Wang Xinmeng and NEIS. As at Thursday, SING-SWE MM Biotechnology has an issued and paid-up share capital of S$100 comprising 100 ordinary shares. NEIS will own the remaining 49 per cent of its issued share capital, down from 70 per cent before the proposed acquisition.
 
In consideration for the sale shares, CFM will allot and issue an aggregate of up to 120 million new fully-paid up ordinary shares in its capital at an issue price of 5.1 cents each to the vendors. This issue price represents a 25.8 per cent discount to the current traded price, and the maximum number of consideration shares to be issued represent some 59.5 per cent of CFM' s existing share capital.
 
SGX RegCo had asked what the group considered before agreeing to such terms. CFM said negotiations with the vendors had commenced prior to May 28, when the counter had a daily trading range of around 3 cents.
 
CFM had also considered that the issue price of 5.1 cents represented only a " small discount" of 2.3 per cent to the group' s net asset value per share.
 
It further said that, as per the deal agreement, the maximum number of consideration shares will be issued only if SING-SWE MM Biotechnology earned a net profit after tax of at least S$2 million, which represents a " significant turnaround" from its loss-making position for the half-year ended Dec 31, 2020.
 
SGX RegCo further asked how CFM arrived at the purchase consideration of S$6.1 million, given that SING-SWE MM Biotechnology is still a new firm.
 
The group said businesses that generated income from activities related to the Covid-19 pandemic have " generally done well" since early 2020, including the manufacture and sale of personal protective equipment such as masks and gloves, and the manufacture and sale of biopharmaceutical products for use against Covid-19, such as testing kits and vaccines.
 
SING-SWE MM Biotechnology owns exclusive distribution rights to certain viral test kits in Europe, Africa, South Asia, South-east Asia and the Middle East, and intends to invest in and develop its own products in related fields.
 
While there are no SGX-listed companies directly comparable to SING-SWE MM Biotechnology, CFM noted that the share price of Top Glove has more than tripled in value since January 2020, and continues to trade at a trailing price-earnings (PE) ratio of more than six times Hyphens Pharma International Limited trades at a trailing PE ratio of almost 15 times.
 
In a separate query, SGX RegCo asked whether CFM has the experience and resources to run the new business. The group said its intention is for SING-SWE MM Biotechnology to continue running the business, with board management and control from CFM.
 
It further said it has been in the business of distribution and sales of personal protective equipment in Singapore, including in the pharmaceutical and healthcare industries, via its subsidiary since January 2015. It therefore believes it has the right experience and network to provide " strategic input" for SING-SWE MM Biotechnology, particularly in Singapore and the region.


 
 
sgtrade     06-Jun-2021 22:59  
Contact    Quote!
Just to check the 5 cent 120 million shares tat is not in the market yet right.

stockman20      ( Date: 06-Jun-2021 21:50) Posted:

whats go up fast will come down fast. at this stage, its too early. dyodd.

 
 
gregtan123     06-Jun-2021 22:42  
Contact    Quote!
Bro do you think we can just short at the open tomorrow? I am not vested but tend to agree with you. 

stockman20      ( Date: 06-Jun-2021 21:50) Posted:

whats go up fast will come down fast. at this stage, its too early. dyodd.

 
Important: Please read our Terms and Conditions and Privacy Policy .